S&P Futures
6,008.00 +4.25 (+0.07%) Dow Futures
43,920.00 +10.00 (+0.02%) Nasdaq Futures
21,248.75 +24.00 (+0.11%) Russell 2000 Futures
2,398.60 +2.90 (+0.12%) Crude Oil
71.89 -0.47 (-0.65%) Gold
2,700.10 -5.70 (-0.21%)
Akero Therapeutics, Inc. (AKRO)
After hours:
| Previous Close | 35.28 |
| Open | 35.26 |
| Bid | 34.79 x 100 |
| Ask | 34.98 x 100 |
| Day's Range | 34.56 - 35.88 |
| 52 Week Range | 13.39 - 37.00 |
| Volume | |
| Avg. Volume | 504,611 |
| Market Cap | 2.45B |
| Beta (5Y Monthly) | -0.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.40 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.78 |
TipRanksMadrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH
Shares of companies developing therapies for the liver disease metabolic steatohepatitis, or MASH, are rallying after Novo Nordisk (NVO) said its GLP-1 drug semaglutide showed “superior improvement” in treating the disease in a trial. Novo Nordisk announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis, or MASH, and moderate to advanced liver fibrosis. Part 1 o
GlobeNewswireAkero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced an upcoming oral presentation and two late-breaking poster presentations at the 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 taking place from November 15-19, 2024, in San Diego. The p
